Page last updated: 2024-12-11
pbc 264
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
pBC 264: CCK agonist; RN given refers to 3H-labeled cpd; RN for unlabeled cpd not avail 10/90; do not confuse with BC 264 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5491702 |
| MeSH ID | M0172604 |
Synonyms (10)
| Synonym |
|---|
| pbc 264 |
| (3s)-4-[[(2s)-1-[[(2s)-3-(1h-indol-3-yl)-2-[[2-oxo-3-[[(1s)-1-[[(2s)-2-(propanoylamino)-3-(4-sulfooxyphenyl)propanoyl]amino]pentyl]amino]propanoyl]amino]propanoyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2s)-2-(methylamino)hexanoyl]amino]-4-oxobutanoi |
| pbc264 |
| 131167-65-2 |
| l-phenylalaninamide, 3-oxo-n-((1s)-1-(((2s)-1-oxo-2-((1-oxopropyl)amino)-3-(4-(sulfooxy)phenyl)propyl)amino)pentyl)-beta-alanyl-l-tryptophyl-n-methyl-l-norleucyl-l-alpha-aspartyl- |
| pbc-264 |
| propionyl-bc264 |
| gtpl3948 |
| (3s)-4-[[(2s)-1-[[(2s)-3-(1h-indol-3-yl)-2-[[2-oxo-3-[[(1s)-1-[[(2s)-2-(propanoylamino)-3-(4-sulfooxyphenyl)propanoyl]amino]pentyl]amino]propanoyl]amino]propanoyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2s)-2-methylaminohexanoyl]amino]-4-oxobutanoic |
| Q27088248 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346921 | Rat CCK2 receptor (Cholecystokinin receptors) | 1996 | European journal of pharmacology, Jan-18, Volume: 296, Issue:1 | His381 of the rat CCKB receptor is essential for CCKB versus CCKA receptor antagonist selectivity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 13.01
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.01) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||